Patient Advocacy

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction issues.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is working to ease care transitions, support community oncologists, and reduce overwhelm in cancer treatment delivery.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the development of innovative cancer therapies.

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are key to closing persistent gaps in preventive care and healthcare access.

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, addresses patient and prescriber expectations for digital health tools.

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.